Monograph of Methotrexate

Introduction

Methotrexate is a synthetic folate antagonist that has established roles in the treatment of malignant neoplasms and a variety of autoimmune disorders. Its mechanism of action is predicated upon competitive inhibition of dihydrofolate reductase (DHFR), thereby attenuating the synthesis of nucleotides required for DNA replication and cell proliferation. The therapeutic spectrum of methotrexate spans from high‑dose regimens administered intravenously for acute leukemia to low‑dose oral or subcutaneous courses prescribed for rheumatoid arthritis (RA), psoriasis, and ectopic pregnancy. The importance of methotrexate within pharmacology curricula lies in its illustrative representation of dose‑dependent toxicity, drug–drug interactions, and the necessity for vigilant monitoring of renal function and hematologic parameters.

Learning objectives for this chapter include:

• Identify the chemical and pharmacokinetic properties of methotrexate.
• Explain the molecular mechanisms underlying its therapeutic and adverse effects.
• Interpret pharmacokinetic equations and calculate key parameters such as C_max and t_1/2.
• Apply clinical guidelines to dose adjustment and monitoring for patients receiving methotrexate.
• Recognize strategies for managing common toxicities and drug interactions.

Fundamental Principles

Core Concepts and Definitions

Methotrexate is a dihydrofolate analog characterized by the presence of a 2,4-diamino-6-[(4-methyl-1,3,5-triazin-2-yl)amino]pyrimidine core. It is lipophilic and exhibits a molecular weight of 454.4 g/mol. The drug is classified as a folate antagonist, a category that includes agents such as pyrimethamine and trimethoprim. Folate antagonists disrupt the folate cycle, which is essential for the generation of thymidylate and purine nucleotides.

Theoretical Foundations

The therapeutic activity of methotrexate is largely attributable to its inhibition of DHFR, an enzyme that reduces dihydrofolate (DHF) to tetrahydrofolate (THF). THF serves as a one‑carbon donor in the synthesis of purines and thymidylate, critical precursors for DNA and RNA. Inhibition of DHFR leads to depletion of THF pools, subsequently impairing nucleotide synthesis and halting cell division. The drug’s affinity for DHFR is higher than that of natural folates, resulting in a potent competitive inhibition. Methotrexate also inhibits thymidylate synthase (TS) at higher concentrations, further compromising DNA synthesis.

Pharmacokinetically, methotrexate follows a biphasic elimination pattern characterized by an initial distribution phase and a slower elimination phase. The drug is primarily excreted unchanged by the kidneys, with a plasma protein binding rate of approximately 40–60%. Its half‑life (t_1/2) ranges from 2 to 10 hours in healthy volunteers, but can extend to 48 hours in patients with renal impairment.

Key Terminology

• DHFR – Dihydrofolate reductase
• THF – Tetrahydrofolate
• TS – Thymidylate synthase
• PK – Pharmacokinetics
• PD – Pharmacodynamics
• MTX – Methotrexate
• Folate cycle – Series of enzymatic reactions involving folate derivatives
• Neutropenia – Reduced neutrophil count
• Hematologic toxicity – Adverse effect involving blood cell lines

Detailed Explanation

Molecular Mechanisms of Action

Methotrexate competitively binds to the catalytic site of DHFR, thereby preventing the reduction of DHF to THF. The inhibition constant (K_i) for MTX is in the low nanomolar range, indicating high potency. The consequence of DHFR blockade is a marked decrease in the intracellular concentration of THF. Since THF is a cofactor for the synthesis of dTMP (deoxythymidine monophosphate) via TS and for purine synthesis via GAR transformylase, the depletion of THF leads to a shortage of nucleotides. DNA replication stalls, and rapidly dividing cells—such as those in malignant tumors or activated lymphocytes—undergo apoptosis or senescence.

At higher drug concentrations, methotrexate accumulates within cells and directly inhibits TS. This dual inhibition amplifies the anti‑proliferative effect, particularly in cancer therapy. Additionally, methotrexate can induce the formation of extracellular adenosine, which exerts anti‑inflammatory effects by binding to A_2A receptors on immune cells, thereby suppressing cytokine release.

Pharmacokinetic Modeling

Following administration, methotrexate concentration in plasma can be described by a two‑compartment model. The general equation for concentration over time is:

C(t) = C₀ × e^-k_elt,

where C₀ is the initial concentration, k_el is the elimination rate constant, and t is time. The half‑life (t_1/2) is related to k_{el> by:}

t_1/2 = ln(2) ÷ k_el.

Absolute bioavailability (F) for oral methotrexate is approximately 50–60%, whereas intravenous administration achieves 100% bioavailability. The area under the concentration–time curve (AUC) is calculated as:

AUC = Dose ÷ Clearance.

Clearance (CL) is the product of renal plasma flow (RPF) and the fraction unbound in plasma (f_u) multiplied by the intrinsic clearance (CL_int), expressed as CL = f_u × CL_int × RPF. In practice, for methotrexate, CL is largely dependent on glomerular filtration, with a minor component of tubular secretion.

Factors Influencing Pharmacokinetics

Age, body mass index, renal function, concomitant medications, and genetic polymorphisms in folate pathway enzymes can alter methotrexate disposition. Renal impairment reduces clearance, prolonging t_1/2 and increasing AUC. Concomitant use of nonsteroidal anti‑inflammatory drugs (NSAIDs) or proton pump inhibitors can inhibit tubular secretion, elevating plasma concentrations. Genetic variations in the MTHFR gene may modify the sensitivity to methotrexate, influencing both efficacy and toxicity.

Mathematical Relationships in Dose Adjustment

When renally excreted drugs such as methotrexate are considered, dose adjustments are often guided by estimated glomerular filtration rate (eGFR). A common approach is to maintain a target AUC by modifying the dose (D) according to:

D = (Target AUC × CL) ÷ Dose,

where CL is recalculated based on the patient’s eGFR. Alternatively, a fixed reduction (e.g., 50% for eGFR 30–60 mL/min) may be applied, followed by therapeutic drug monitoring (TDM).

Clinical Significance

Drug Therapy Relevance

The anti‑proliferative properties of methotrexate have been harnessed for both oncologic and rheumatologic indications. In oncology, high‑dose intravenous methotrexate (≥15 mg/m²) is employed in acute lymphoblastic leukemia and osteosarcoma. In rheumatology, low‑dose oral or subcutaneous methotrexate (7.5–25 mg weekly) is the first‑line disease‑modifying antirheumatic drug (DMARD) for RA. Its utility in psoriasis, ectopic pregnancy, and certain dermatologic malignancies further underscores its versatility.

Practical Applications

Clinicians are required to balance therapeutic benefits against the risk of toxicity. Common adverse effects include mucositis, hepatotoxicity, bone marrow suppression, and renal impairment. Monitoring strategies involve baseline and periodic assessment of complete blood count (CBC), liver function tests (LFTs), serum creatinine, and serum methotrexate levels, particularly after high‑dose regimens. The use of folinic acid (leucovorin) rescue is standard after high‑dose methotrexate to mitigate toxicity without compromising antitumor activity.

Clinical Examples

A 45‑year‑old woman with seropositive RA is initiated on 15 mg weekly methotrexate. Baseline CBC and LFTs are normal. She reports mild fatigue after the first cycle. Over the next six months, her C_max remains within the therapeutic window, and no significant elevation in liver enzymes is observed. Her disease activity score (DAS28) declines from 5.8 to 3.2, indicating partial remission. The clinician continues the regimen, adding folic acid 1 mg daily to reduce the risk of mucositis.

Conversely, a 60‑year‑old man with metastatic colorectal cancer receives 20 mg/m² intravenous methotrexate. Post‑infusion serum levels remain elevated at 24 hours, prompting the administration of 10 mg leucovorin and aggressive hydration. Subsequent renal function declines, necessitating a reduction in the dose to 10 mg/m² in future cycles.

Clinical Applications/Examples

Case Scenario 1 – Low‑Dose Methotrexate in RA

Patient profile: 52‑year‑old female, BMI 28 kg/m², eGFR 75 mL/min. Diagnosis: seropositive RA, DAS28 5.6. Treatment plan: oral methotrexate 15 mg weekly, folic acid 1 mg daily, NSAID for pain. Monitoring schedule: CBC and LFTs at baseline, 4 weeks, 8 weeks, then every 3 months. Outcome: after 12 weeks, DAS28 decreases to 3.8; CBC remains stable; LFTs within normal limits. Adjustments: increase methotrexate to 20 mg weekly after 6 months if disease activity persists above 3.2; continue folic acid supplementation.

Case Scenario 2 – High‑Dose Methotrexate in Acute Lymphoblastic Leukemia

Patient profile: 7‑year‑old boy, B‑cell ALL, presenting with high leukocyte count. Induction regimen: 15 mg/m² intravenous methotrexate on days 1, 8, 15, 22. Rescue: leucovorin 10 mg IV every 6 hours starting 24 hours after infusion, based on serum methotrexate level. Monitoring: serum methotrexate levels at 24, 48, 72 hours; CBC and creatinine daily. Outcome: serum methotrexate levels fall below 0.1 µmol/L at 72 hours; no evidence of mucositis or neutropenia. Subsequent consolidation therapy proceeds with adjusted dosing.

Problem‑Solving Approaches

When methotrexate toxicity is suspected, the first step is to confirm serum concentration. If levels exceed 1 µmol/L at 24 hours, leucovorin rescue is intensified. In cases of renal impairment, hydration and alkalinization of urine are recommended to enhance excretion. For patients on concurrent NSAIDs, discontinuation or dose reduction may be considered to mitigate the risk of impaired clearance. Genetic testing for MTHFR polymorphisms can be discussed when unexpected toxicity occurs despite appropriate dosing.

Summary/Key Points

• Methotrexate is a folate antagonist that inhibits DHFR and, at higher concentrations, TS, thereby impairing DNA synthesis.
• Pharmacokinetics are characterized by a biphasic elimination, renal excretion, and a t_1/2 ranging from 2 to 48 hours depending on renal function.
• Key equations: C(t) = C₀ × e^-k_elt, t_1/2 = ln(2) ÷ k_el, AUC = Dose ÷ Clearance.
• Clinical monitoring should include CBC, LFTs, serum creatinine, and methotrexate levels, particularly after high‑dose therapy.
• Leucovorin rescue and folic acid supplementation are essential components of toxicity management.
• Renal function dictates dose adjustments; eGFR < 30 mL/min warrants significant dose reduction or discontinuation.
• Drug interactions with NSAIDs, proton pump inhibitors, and other agents that impair renal clearance must be anticipated and managed.
• Patient education on adherence, potential side effects, and the importance of regular laboratory monitoring enhances therapeutic outcomes.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
3. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
4. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
5. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.